This action makes these agents a therapeutic option for weight loss.56 Although to a lesser extent, delay in gastric emptying contributes to the anorexigenic effect.61 Clinical trials conducted with GLP-1 receptor agonists in patients with obesity (or excess weight [BMI 27] with comorbidities), or with DT2 and excess weight or obesity, have achieved weight reductions greater than those reported for orlistat, as well as those observed with oral antidiabetic agents such as the sodium glucose type 2 cotransporter inhibitors (SGLT2i) or metformin.62 In a meta-analysis of more than 10 000 patients with obesity, those treated with GLP-1 receptor agonists lost, on average, 7kg more than those in the control group.63 Weight loss of up to 15% has been observed after 12 months of treatment,64,65 a level that had only been achieved through surgical methods
Up-titration can be slowed to limit severity and frequency of side effects
Consistent with these findings, downregulation of Grx5 sensitizes cisplatin-resistant head and neck cancer towards ferroptosis [135]
Notably, mitochondrial Trx2 contains the active site motif found in Trx1 but lacks additional structural cysteines, proposed to modulate its function as regulatory sites [11,12]
Keeping a journal of your experiences can be a helpful way to identify patterns and to monitor when the positive effects consistently begin to manifest
